Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Mosunetuzumab Demonstrates High Response Rates in Treatment-Naive MZL

September 5th 2025, 10:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

Orca-T Improves Moderate to Severe cGVHD-Free Survival in Hematologic Malignancies

September 5th 2025, 6:43pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies

Dr Loghavi on SOC Frontline Testing Approaches in MDS

September 5th 2025, 4:19pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma

September 5th 2025, 3:02pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Dr Jagannath on the Potential Role of MRD Testing for Defining "Cure" in Myeloma

September 5th 2025, 1:49pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sundar Jagannath, MBBS, explores how minimal residual disease could redefine what it means to achieve a "cure" in multiple myeloma.

Dr Palandri on Efforts to Elucidate the Role of Predictive Markers for Ruxolitinib in Myelofibrosis

September 5th 2025, 1:39pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Francesca Palandri, MD, discusses research needed to clarify the role of predictive markers for ruxolitinib response in myelofibrosis.

Dr Florez on the Significance of a Consensus Manuscript From the BTG Lung Cancer Conference

September 4th 2025, 9:30pm

Bridging the Gaps in Lung Cancer

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML

September 4th 2025, 9:08pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Peak CAR T-Cell Expansion Associated With Reduced Relapse Risk Following Brexu-Cel Consolidation in B-ALL

September 4th 2025, 8:15pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL

September 4th 2025, 7:21pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Zanubrutinib bested acalabrutinib plus venetoclax in terms of PFS in patients with treatment-naive, low-risk CLL.

Meta-Analysis Highlights Efficacy, Safety Benefits With Asciminib in Chronic Myeloid Leukemia

September 4th 2025, 6:45pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

Venetoclax Plus Azacitidine Fails to Provide OS Advantage in Treatment-Naive, Higher-Risk MDS

September 4th 2025, 6:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

Zanubrutinib Prolongs PFS, Shows Trend Toward Improved OS in MAIC Analysis in CLL

September 4th 2025, 5:10pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

Olutasidenib Monotherapy Yields Responses in Primary Refractory IDH1-Mutant AML

September 4th 2025, 4:20pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Dr Élez on Health-Related QOL With Nivolumab Plus Ipilimumab in mCRC

September 2nd 2025, 8:50pm

ESMO Gastrointestinal Cancers Congress

Elena Élez, MD, PhD, discusses health-related QOL data with nivolumab plus ipilimumab in mCRC.

Dr Mouabbi on Areas for Further Investigation in HER2+ Breast Cancer

August 28th 2025, 9:19pm

Bridging the Gaps in Breast Cancer

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Experts Highlight Key Topics to Watch at the IASLC 2025 World Conference on Lung Cancer

August 28th 2025, 1:00pm

IASLC World Conference on Lung Cancer

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

Dr Malhotra on Persisting Knowledge Gaps Surrounding the Use of ADCs in Lung Cancer

August 27th 2025, 7:21pm

Bridging the Gaps in Lung Cancer

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLC

August 22nd 2025, 5:33pm

Bridging the Gaps in Lung Cancer

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025, 1:00pm

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.